Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 11,000 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 11,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00. Following the sale, the insider directly owned 416,775 shares of the company’s stock, valued at approximately $7,501,950. This represents a 2.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Wednesday, March 11th, Susan Bobulsky sold 41,338 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.17, for a total transaction of $544,421.46.

Adaptive Biotechnologies Trading Down 1.2%

Shares of NASDAQ ADPT opened at $16.70 on Tuesday. Adaptive Biotechnologies Corporation has a 12-month low of $9.90 and a 12-month high of $20.76. The stock has a market cap of $2.67 billion, a PE ratio of -50.61 and a beta of 2.16. The company has a 50-day moving average of $14.22 and a 200 day moving average of $15.65.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. During the same quarter in the prior year, the company earned ($0.20) EPS. Adaptive Biotechnologies’s revenue was up 35.1% compared to the same quarter last year. On average, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. dropped their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Guggenheim reissued a “buy” rating and issued a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. TD Cowen increased their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Morgan Stanley dropped their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.57.

Hedge Funds Weigh In On Adaptive Biotechnologies

Hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $28,000. EverSource Wealth Advisors LLC boosted its position in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the period. KBC Group NV purchased a new position in shares of Adaptive Biotechnologies during the 1st quarter worth approximately $45,000. Assetmark Inc. boosted its position in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $51,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.